NCT04046263View on ClinicalTrials.gov

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 1, 2020

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions
Peritoneal Dialysis ComplicationHyperphosphatemiaHypoalbuminemia
Interventions
DRUG

Sucroferric Oxyhydroxide Chewable Tablet

Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal

Trial Locations (1)

80045

University of Colorado Anschutz Medical Campus, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT04046263 - Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients | Biotech Hunter | Biotech Hunter